
WHAT IS CLAIMED:

1. Compound **1**:



Compound **1**

or a pharmaceutically acceptable salt, tautomer, solvate or hydrate thereof, for use in treating or preventing inflammatory bowel disease in a patient in need thereof.

2. The compound of claim 1, wherein the inflammatory bowel disease is ulcerative colitis.

3. The compound of claim 2, wherein the ulcerative colitis is mild to moderate ulcerative colitis, , or wherein the ulcerative colitis is moderate to severe ulcerative colitis.

4. The compound of claim 2, wherein the ulcerative colitis is ulcerative proctitis, proctosigmoiditis, left-sided colitis, or pan-ulcerative colitis.

5. The compound of claim 2, wherein the patient has undergone prior treatment for ulcerative colitis or is currently being treated with an anti-inflammatory drug.

6. The compound of claim 1, wherein the inflammatory bowel disease is Crohn's disease.

7. The compound of claim 6, wherein the Crohn's disease is ileocolitis, ileitis, gastroduodenal Crohn's disease, jejunoileitis, or Crohn's (granulomatous) colitis.

8. The compound of claim 6, wherein the patient has a Crohn's Disease Activity Index ("CDAI") score greater than or equal to 150 and less than or equal to 220, greater than or equal to 220 and less than or equal to 300, or greater than 300.

9. The compound of claim 1, wherein the composition is administered daily.

10. The compound of claim 1, wherein the oral bioavailability of Compound **1** is less than 10%.

11. The compound of claim 1, wherein the compound is delivered with negligible systemic absorption to the intestinal epithelium of the patient, to the colon of the patient, or to the lining of the descending colon of the patient.

12. The compound of claim 1, wherein serum levels of the compound in the patient are negligible at a time after administration of the compound.

13. The compound of claim 1, wherein the change in hemoglobin levels in the patient are negligible six hours after administration of the compound, or wherein the change in EPO levels in the patient are negligible six hours after oral administration of the compound, or wherein the change in red blood cell levels in the patient are negligible six hours after oral administration of the compound.

14. The compund of claim 1, wherein the patient is at risk of developing a cardiovascular disease.

15. The compound of claim 14, wherein the patient has experienced a cardiovascular event in the last two years.

16. The compound of claim 15, wherein the cardiovascular event is a heart attack or stroke.

17. The compound of claim 1, wherein the patient has a disorder in which angiogenesis is contraindicated or in which erythropoiesis is contraindicated.

18. The compound of claim 1, wherein Compound **1** is administered as an oral formulation.

19. The compound of claim 18, wherein the oral formulation is a tablet or capsule.

20. The compound of claim 18, wherein the oral formulation does not comprise an enteric coating.